Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 12/20 | 0.81 |
| ▸ | CHRNB2 | P17787 | 12/20 | 0.66 |
| ▸ | CHRNA4 | P43681 | 12/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL834978 | 0.89 | CHRNA7 (1.00) | CHRNA7CHRNB2CHRNA4 | |
| SCHEMBL6208322 | 0.80 | CHRNA7 (0.77) | CHRNA7CHRNB2CHRNA4 | |
| SCHEMBL373001 | 0.79 | CHRNB2 (1.00) | CHRNA7CHRNB2CHRNA4 | |
| Hydrochloric Acid SCHEMBL6208049 | 0.79 | CHRNA7 (0.76) | CHRNA7CHRNB2CHRNA4 | |
| SCHEMBL373208 | 0.78 | CHRNB2 (0.88) | CHRNA7CHRNB2CHRNA4 | |
| SCHEMBL6882505 | 0.77 | CHRNA7 (0.60) | CHRNA7CHRNB2CHRNA4 | |
| SCHEMBL373018 | 0.77 | CHRNA7 (0.84) | CHRNA7CHRNB2CHRNA4 | |
| SCHEMBL372864 | 0.76 | CHRNA7 (0.83) | CHRNA7CHRNB2CHRNA4 | |
| SCHEMBL1741511 | 0.75 | CHRNB2 (1.00) | CHRNA7CHRNB2CHRNA4 | |
| SCHEMBL372727 | 0.75 | CHRNA7 (1.00) | CHRNA7CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7754189-B2 | 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof | TARGACEPT, INC. (US) | 2010-07-13 | — | — | US | disclosed |
| US-7754189-B2 | 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof | TARGACEPT, INC. (US) | 2010-07-13 | — | — | US | disclosed |
| US-20080138287-A1 | 3-SUBSTITUTED-2(ARYLALKYL)-1- AZABICYCLOALKANES AND METHODS OF USE THEREOF | ATTENUA, INC. | 2008-06-12 | — | — | US | disclosed |
| US-20080138287-A1 | 3-SUBSTITUTED-2(ARYLALKYL)-1- AZABICYCLOALKANES AND METHODS OF USE THEREOF | ATTENUA, INC. | 2008-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080138287-A1 | 3-SUBSTITUTED-2(ARYLALKYL)-1- AZABICYCLOALKANES AND METHODS OF USE THEREOF | CHRNA7, CHRNA5, CHRNA3 | CHRNA7 1/4885CHRNB2 16/4885CHRNA4 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.